377 related articles for article (PubMed ID: 32630618)
1. Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy.
Cuyàs E; Verdura S; Martin-Castillo B; Alarcón T; Lupu R; Bosch-Barrera J; Menendez JA
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630618
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
3. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.
Bai X; Yi M; Jiao Y; Chu Q; Wu K
Onco Targets Ther; 2019; 12():9527-9538. PubMed ID: 31807028
[TBL] [Abstract][Full Text] [Related]
4. Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy.
Luby A; Alves-Guerra MC
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885023
[TBL] [Abstract][Full Text] [Related]
5. Immunometabolism: a new dimension in immunotherapy resistance.
Xiao C; Xiong W; Xu Y; Zou J; Zeng Y; Liu J; Peng Y; Hu C; Wu F
Front Med; 2023 Aug; 17(4):585-616. PubMed ID: 37725232
[TBL] [Abstract][Full Text] [Related]
6. Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy.
Zhu X; Zhu L; Wu Y
Curr Protein Pept Sci; 2022; 23(9):585-601. PubMed ID: 35726423
[TBL] [Abstract][Full Text] [Related]
7. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
8. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
Huang L; Xu H; Peng G
Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
[TBL] [Abstract][Full Text] [Related]
9. Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy.
Coleman MF; Cozzo AJ; Pfeil AJ; Etigunta SK; Hursting SD
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32244756
[TBL] [Abstract][Full Text] [Related]
10. Altered cancer metabolism in mechanisms of immunotherapy resistance.
Ramapriyan R; Caetano MS; Barsoumian HB; Mafra ACP; Zambalde EP; Menon H; Tsouko E; Welsh JW; Cortez MA
Pharmacol Ther; 2019 Mar; 195():162-171. PubMed ID: 30439456
[TBL] [Abstract][Full Text] [Related]
11. Tissue biomarkers of immune checkpoint inhibitor therapy.
Davoudi F; Moradi A; Sadeghirad H; Kulasinghe A
Immunol Cell Biol; 2024 Mar; 102(3):179-193. PubMed ID: 38228572
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
13. The interplay between metabolic adaptations and diet in cancer immunotherapy.
Espelage L; Wagner N; Placke JM; Ugurel S; Tasdogan A
Clin Cancer Res; 2024 May; ():. PubMed ID: 38771898
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors.
Li X; Yang Y; Huang Q; Deng Y; Guo F; Wang G; Liu M
Front Cell Dev Biol; 2021; 9():738373. PubMed ID: 34692696
[TBL] [Abstract][Full Text] [Related]
15. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Kok VC
Front Oncol; 2020; 10():268. PubMed ID: 32185135
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
17. Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.
Zhang X; Li H; Lv X; Hu L; Li W; Zi M; He Y
Life (Basel); 2022 Mar; 12(3):. PubMed ID: 35330159
[TBL] [Abstract][Full Text] [Related]
18. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.
Anagnostou V; Landon BV; Medina JE; Forde P; Velculescu VE
Sci Transl Med; 2022 Nov; 14(670):eabo3958. PubMed ID: 36350985
[TBL] [Abstract][Full Text] [Related]
19. Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment.
Wu D
Adv Exp Med Biol; 2017; 1011():211-223. PubMed ID: 28875492
[TBL] [Abstract][Full Text] [Related]
20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
